IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer

NCT00300586 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

842

Enrollment

OTHER

Sponsor class

Conditions

Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: observation
DRUG: gemcitabine
DRUG: erlotinib

Sponsor

Hospices Civils de Lyon